Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Baculovirus-Based Minimally Invasive Therapy for Head and Neck Squamous Cell Carcinoma

Award Number: R01DE035485
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/06/2026
PERIOD OF PERFORMANCE END DATE: 07/31/2031

Group Awards By:

View Award Description

Baculovirus-Based Minimally Invasive Therapy for Head and Neck Squamous Cell Carcinoma - PROJECT SUMMARY Head and neck squamous cell carcinoma (HNSCC) arises from the mucosal epithelium of the oral cavity, pharynx, and larynx. Given the critical functional and structural roles of these tissues, preserving their integrity during cancer treatment is essential. However, approximately 50% of patients undergoing current standard treatments experience local recurrence, largely due to the presence of a substantial precancerous field near the tumor margin. This underscores an urgent need for effective, minimally invasive therapies for HNSCC. This project seeks to develop an in vivo gene editing system leveraging baculoviral vectors for HNSCC treatment. Advances in CRISPR gene editing have revolutionized the potential to treat intractable genetic diseases by enabling precise modifications of specific genomic loci. Unlike traditional gene therapy, RNA-guided CRISPR technology can target nearly any gene and simultaneously modify multiple targets. Nonetheless, the therapeutic application of in vivo CRISPR remains hindered by off-target effects, which risk introducing harmful mutations in normal tissues. Our proposed system utilizes baculoviral vectors (BVs) derived from an insect virus, which are highly biocompatible and capable of efficiently transducing a wide range of mammalian cells, including dormant stem cells. Importantly, BVs have a large DNA packaging capacity, allowing them to carry CRISPR components along with genetic regulatory elements. Preliminary studies in our lab demonstrated that BVs conjugated with magnetic nanoparticles can be locally activated via an external magnetic device, and BV-mediated Pdl1 disruption significantly suppressed tumor growth and improved survival in a mouse syngeneic colon cancer model. Building on this success, we propose integrating nanoparticle-mediated viral transduction with a microRNA (miR)-based cell classifier to achieve precise, cell-specific gene disruptions. Our central hypothesis is that combining nanotechnology with synthetic biology circuits will enable BVs to target cancer cells efficiently and specifically, offering a minimally invasive therapy for HNSCC with cellular precision. By disrupting oncogenes and immune checkpoints, this approach aims to eliminate cancer cells and elicit a durable immune response to prevent recurrence. The study will employ clinically relevant models, including two mouse syngeneic oral cancer models and a patient-derived organotypic tumor slice culture model. If successful, this research will pave the way for a novel therapeutic strategy that delivers precise, durable, and minimally invasive treatment for HNSCC patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $591,176 )
2026	2026	UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE	500 S LIMESTONE	LEXINGTON	KY	40526	FAYETTE	USA	Oral Diseases and Disorders Research	000	1	8/10/2026	NEW	$591,176
														Subtotal = $591,176

Grand Total All Awards = $591,176

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Baculovirus-Based Minimally Invasive Therapy for Head and Neck Squamous Cell Carcinoma

Award Number: R01DE035485

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/06/2026

PERIOD OF PERFORMANCE END DATE: 07/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer